UBS analyst Jo Walton maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi SAN-1.02%decrease; red down pointing triangle posted better-than-expected earnings and sales in the third quarter, ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...